Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03477045
Other study ID # 17497
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 9, 2017
Est. completion date November 4, 2019

Study information

Verified date June 2022
Source University of Southampton
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fish oil and oily fish contain omega 3 long chain polyunsaturated fatty acids known to be beneficial to health. Many people consume little, despite UK government recommendations to eat at least one portion of oily fish per week. Furthermore, despite modest consumption, fish stocks are declining due to over fishing. Therefore, there is a need for an alternative, sustainable and cost efficiently produced dietary source. A seed oil source of these fish oil-type fatty acids has been achieved by adding genes from other plant sources to the oil seed plant Camelina sativa. Camelina sativa, related to mustard and cabbage, has provided seed oil for human consumption for thousands of years. It was the most important oil seed plant in Europe until the 1900's. This research is being done to see if consuming fish oil-type fatty acids in Camelina seed oil allows the body to take up and use the fish oil fatty acids in the same way as it does from fish oil.


Description:

This research is being done to see if consuming fish oil-type omega 3 long chain polyunsaturated fatty acids in Camelina seed oil allows the body to take up the fish oil fatty acids in the same way as it does from fish oil. In the first study (A) the Camelina oil will be used in a meal. The volunteers (healthy men and women) will be asked to consume the meal and provide blood samples in the following 6 hours to look at immediate uptake of the fish oil fatty acids. This will be repeated (for comparison) with fish oil. The second study (B) will look at consumption over a longer period. Volunteers will be asked to consume the Camelina oil daily for 8 weeks and provide blood samples at the visits at the start and end of that period. This will be repeated (for comparison) with fish oil.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date November 4, 2019
Est. primary completion date November 4, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male or female 2. 18 to 30 years or 50 to 65 years 3. Body mass index 18.5-30.0 kg/m2 4. Health screening results that are within normal clinical ranges 5. Not consuming fish oil or other oil supplements 6. Not eating more than one oily fish meal per week 7. Willing to adhere to the study protocol 8. Being able to provide written informed consent Exclusion Criteria: 1. Aged < 18 years; 31-49 years or > 65 years 2. Body mass index < 18.5 or > 30 kg/m2 3. Current smoker 4. Fasting blood cholesterol or glucose concentrations outside the normal concentration range 5. Diagnosed chronic illness (for example diagnosed cardiovascular disease, diabetes, cancer) 6. Use of prescribed medicine to control inflammation 7. Use of prescribed medication to control blood lipids (e.g. statins, fibrates (fenofibrate), Omacor) 8. Use of prescribed medication to control blood pressure (ACE inhibitors, angiotensin 2 receptor blockers, calcium channel blockers, a-inhibitors, thiazide diuretics) 9. Use of fish oil or other oil supplements 10. Chronic gastrointestinal problems (e.g. IBD, coeliac disease, cancer) 11. Pregnant or planning to become pregnant within the study period 12. Participation in another clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Single dose fish oil
Fish oil consumed within a single high fat test meal
Repeated dose fish oil
Fish oil consumed daily for 8 weeks
single dose Camelina seed oil
camelina seed oil consumed within a single high fat test meal
repeated dose camelina seed oil
camelina seed oil consumed daily for 8 weeks

Locations

Country Name City State
United Kingdom Faculty of Medicine, University of Southampton Southampton Hants

Sponsors (1)

Lead Sponsor Collaborator
University of Southampton

Country where clinical trial is conducted

United Kingdom, 

References & Publications (4)

West AL, Michaelson LV, Miles EA, Haslam RP, Lillycrop KA, Georgescu R, Han L, Napier JA, Calder PC, Burdge GC. Lipidomic Analysis of Plasma from Healthy Men and Women Shows Phospholipid Class and Molecular Species Differences between Sexes. Lipids. 2021 — View Citation

West AL, Michaelson LV, Miles EA, Haslam RP, Lillycrop KA, Georgescu R, Han L, Sayanova O, Napier JA, Calder PC, Burdge GC. Differential postprandial incorporation of 20:5n-3 and 22:6n-3 into individual plasma triacylglycerol and phosphatidylcholine molec — View Citation

West AL, Miles EA, Lillycrop KA, Han L, Napier JA, Calder PC, Burdge GC. Dietary supplementation with seed oil from transgenic Camelina sativa induces similar increments in plasma and erythrocyte DHA and EPA to fish oil in healthy humans. Br J Nutr. 2020 — View Citation

West AL, Miles EA, Lillycrop KA, Napier JA, Calder PC, Burdge GC. Genetically modified plants are an alternative to oily fish for providing n-3 polyunsaturated fatty acids in the human diet: A summary of the findings of a Biotechnology and Biological Scie — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Uptake of omega 3 polyunsaturated fatty acids after short term consumption of fish oil or Camelina seed oil. The magnitude of the increase in omega 3 polyunsaturated fatty acids in plasma lipids and blood cells following consumption of modified Camelina seed oil for short (postprandial) period compared with fish oil. Short term consumption - single dose followed over 8 hours
Primary Uptake of omega 3 polyunsaturated fatty acids after longer term consumption of fish oil or Camelina seed oil. The magnitude of the increase in omega 3 polyunsaturated fatty acids in plasma lipids and blood cells following consumption of modified Camelina seed oil for 8 weeks compared with fish oil. Longer term consumption daily for 8 weeks. Follow up at 8 weeks.
Secondary Effect of omega 3 polyunsaturated fatty acid consumption on postprandial inflammatory markers after consumption of fish oil or Camelina seed oil. To measure the appearance of inflammatory mediators in the blood of healthy subjects over 8 hours following consumption of a standard high fat meal containing modified Camelina seed oil compared with consuming the same meal containing fish oil. Short term consumption - single dose followed over 8 hours
Secondary Effect of omega 3 polyunsaturated fatty acid consumption for 8 weeks on in vitro immune responses after consumption of fish oil or Camelina seed oil. To measure in vitro immune responses (immune cells inflammatory markers and response to bacterial challenge) by peripheral blood mononuclear cells following consumption of modified Camelina seed oil for 8 weeks compared with consuming fish oil for the same duration. Longer term consumption daily for 8 weeks. Follow up at 8 weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1